Jason C. Legg

3.4k total citations · 2 hit papers
37 papers, 2.0k citations indexed

About

Jason C. Legg is a scholar working on Oncology, Surgery and Hematology. According to data from OpenAlex, Jason C. Legg has authored 37 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Surgery and 7 papers in Hematology. Recurrent topics in Jason C. Legg's work include Neutropenia and Cancer Infections (12 papers), Lipoproteins and Cardiovascular Health (7 papers) and Blood disorders and treatments (6 papers). Jason C. Legg is often cited by papers focused on Neutropenia and Cancer Infections (12 papers), Lipoproteins and Cardiovascular Health (7 papers) and Blood disorders and treatments (6 papers). Jason C. Legg collaborates with scholars based in United States, United Kingdom and Belgium. Jason C. Legg's co-authors include Scott M. Wasserman, Jennifer G. Robinson, Robert C. Scott, Ransi Somaratne, Marc S. Sabatine, Robert P. Giugliano, Michael J. Koren, Dirk Blom, Stephen D. Wiviott and Frederick J. Raal and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Jason C. Legg

35 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

2014 407 citations Jennifer G. Robinson, Jason C. Legg et al. profile →

Peers

Countries citing papers authored by Jason C. Legg

Since Specialization

Citations

This map shows the geographic impact of Jason C. Legg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason C. Legg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason C. Legg more than expected).

Fields of papers citing papers by Jason C. Legg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason C. Legg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason C. Legg. The network helps show where Jason C. Legg may publish in the future.

Co-authorship network of co-authors of Jason C. Legg

This figure shows the co-authorship network connecting the top 25 collaborators of Jason C. Legg. A scholar is included among the top collaborators of Jason C. Legg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason C. Legg. Jason C. Legg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of serum and brain cytokine levels following prolonged binge-like methamphetamine self-administration and cued methamphetamine seeking 2025 ·Journal of Neuroimmunology ·(unknown), (unknown), Jason C. Legg, (unknown), M. Foster Olive	0
2	BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE) 2020 ·Journal of the American College of Cardiology ·John R. Teerlink, Rafael Díaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Scott Solomon, Jason C. Legg, Claire Varin, Christopher E. Kurtz, Fady I. Malik, Siddique Abbasi	2
3	EFFECT OF OMECAMTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF 2019 ·Journal of the American College of Cardiology ·John R. Teerlink, G. Michael Felker, John J.V. McMurray, Scott D. Solomon, John G.F. Cleland, Steven R. Goldsmith, Christopher E. Kurtz, Gustavo Büchele, Jason C. Legg, Fady I. Malik, Narimon Honarpour	1
4	Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting 2016 ·SpringerPlus ·Ricardo Dent, (unknown), C. Stephen Djedjos, Jason C. Legg, Mary Elliott, Michelle Geller, Dawn Meyer, Ransi Somaratne, Chris Recknor, Robert Weiss	20
5	A COMPREHENSIVE SAFETY ANALYSIS OF 6026 PATIENTS FROM PHASE 2 AND 3 SHORT AND LONG TERM CLINICAL TRIALS WITH EVOLOCUMAB (AMG 145) 2015 ·Journal of the American College of Cardiology ·Peter P. Tóth, Naveed Sattar, Jacques Genest, Olivier Descamps, Ricardo Dent, C. Stephen Djedjos, Jason C. Legg, Scott M. Wasserman, Evan A. Stein	8
6	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events breakdown → 2015 ·New England Journal of Medicine ·Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk Blom, Jennifer G. Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason C. Legg, Scott M. Wasserman, Robert C. Scott, Michael J. Koren, Evan A. Stein	1091
7	Discrete Choice Experiment to Estimate Breast Cancer Patients’ Preferences and Willingness to Pay for Prophylactic Granulocyte Colony-Stimulating Factors 2014 ·Value in Health ·Phaedra Johnson, Tim Bancroft, Richard Barron, Jason C. Legg, Xiaoyan Li, (unknown), Arash Naeim, (unknown), Deborah A. Marshall	32
8	Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases 2013 ·BMC Health Services Research ·Derek Weycker, Oleg Sofrygin, (unknown), Robert G Deeter, Jason C. Legg, John Edelsberg	43
9	Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices 2013 ·Clinical Drug Investigation ·(unknown), Arletta van Breda, Patricia K. Corey‐Lisle, Sanatan Shreay, Ze Cong, Jason C. Legg	1
10	A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia 2013 ·Journal of Medical Economics ·Brian Dulisse, Xiaoyan Li, Julie Gayle, Richard Barron, Frank R. Ernst, Kenneth J. Rothman, Jason C. Legg, James A. Kaye	70
11	Estimating multiple treatment effects using two-phase semiparametric regression estimators 2013 ·Electronic Journal of Statistics ·Cindy Yu, Jason C. Legg, (unknown)	1
12	PCN122 Pilot Survey to Estimate Willingness to Pay (WTP) for Prophylactic Granulocyte Colony-Stimulating Factors (G-CSFs) Among Previously Treated Breast Cancer Patients 2012 ·Value in Health ·(unknown), Tim Bancroft, Richard Barron, Jason C. Legg, (unknown), Arash Naeim, (unknown), Deborah A. Marshall	1
13	Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care 2012 ·International Journal of Hematology ·Roberto Stasi, (unknown), Marc Michel, Jean‐François Viallard, Aristoteles Giagounidis, Ann Janssens, Jason C. Legg, Robert Deuson, Mark D. Danese	18
14	Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent 2012 ·Supportive Care in Cancer ·Robert Pirker, Melissa Pirolli, (unknown), (unknown), Jason C. Legg, Helen Collins, Johan Vansteenkiste	14
15	A comparison of sample set restriction procedures 2011 ·Quality Engineering ·Jason C. Legg, Cindy Yu	4
16	PCN129 USE OF ELECTRONIC MEDICAL RECORDS (EMR) FOR ONCOLOGY OUTCOMES RESEARCH: ASSESSING THE COMPARABILITY OF EMR INFORMATION TO PATIENT REGISTRY AND HEALTH CLAIMS DATA 2011 ·Value in Health ·(unknown), Fionna Mowat, Michael A. Kelsh, Jason C. Legg, Nicole Engel-Nitz, (unknown), Helen Collins, Robert J. Nordyke, Joanna L. Whyte	5
17	Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer 2011 ·PharmacoEconomics ·Robert I. Griffiths, Richard Barron, Michelle Gleeson, Mark D. Danese, Anthony O’Hagan, Victoria M. Chia, Jason C. Legg, Gary H. Lyman	10
18	Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial 2011 ·Medical Oncology ·Jean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, Pere Gascón, Carsten Bokemeyer, Heinz Ludwig, Jan B. Vermorken, Jason C. Legg, (unknown), (unknown)	12
19	Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue 2010 ·Contemporary Clinical Trials ·Donald E. Stull, Margaret Vernon, Jason C. Legg, Hema N. Viswanathan, Diane L. Fairclough, Dennis A. Revicki	6
20	Characterization of P-glycoprotein inhibition at the blood brain barrier by ketoconazole and quinidine using the central pharmacodynamics of loperamide as an indicator of brain distribution 2005 ·Clinical Pharmacology & Therapeutics ·Terence Fullerton, Martin M. Bednar, (unknown), Jason C. Legg, David Hoelscher, (unknown), Megan Gibbs	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact